CS-2034 mRNA Booster Shows Strong Variant-Neutralizing Antibody Responses, but Faster Decline in Older Adults
Background: How does the antibody response change after a booster?
Adults who received a booster of the messenger RNA (mRNA) vaccine CS-2034 showed a stronger neutralizing antibody response than those who received an inactivated vaccine booster. However, antibody levels declined faster after vaccination in older adults. These findings come from a follow-up study examining immune responses by age and before and after breakthrough infection; they do not directly establish how well vaccination prevents infection or severe disease.
The emergence of SARS-CoV-2 variants has prompted evaluation of the durability of immune responses after vaccination and responses against variant strains. This study compared a heterologous booster, using a different type of vaccine, with an inactivated vaccine booster in healthy adults who had received at least three doses of inactivated vaccine. The main assessments included antibody levels and their changes over time after boosting, responses after breakthrough infection, and age-related differences.
Key findings: Immune markers in 64 participants and comparisons before and after breakthrough infection
This follow-up study was based on an existing randomized, double-blind, parallel-group controlled trial. It included 64 participants: 32 aged 18–59 and 32 aged 60 or older. Each age group comprised 24 participants in the mRNA vaccine group and 8 in the inactivated vaccine group. Pregnant people, people with severe chronic diseases, and people with a history of allergies were excluded.
The researchers measured neutralizing antibodies using a microneutralization assay and assessed inhibition of binding between angiotensin-converting enzyme 2 (ACE2) and the viral receptor-binding domain (RBD) using a high-sensitivity electrochemiluminescence assay. Both assays provide indicators of immune response and should be distinguished from actual rates of infection or severe disease.
The mRNA vaccine group showed stronger and more consistent neutralizing antibody responses against the ancestral strain and variants such as XBB and BA.5. Antibody increases after breakthrough infection were also greater and more sustained in the mRNA vaccine group, while increases in the inactivated vaccine group were comparatively smaller. However, the provided abstract does not report the fold increase in antibody levels or exactly how long the elevated levels persisted.
Changes over time also differed. Among older participants in the mRNA vaccine group, antibody levels declined faster after vaccination. In the inactivated vaccine group, antibody levels were reported to rise temporarily at three months before declining. ACE2–RBD binding inhibition was higher early on in the mRNA vaccine group. In the inactivated vaccine group, it rose later, at three months, and then fell.
Meaning and outlook: Assess both the magnitude and durability of antibody responses
These results provide a basis for considering vaccine type, age, and breakthrough infection history together when studying booster strategies in adults previously vaccinated with inactivated vaccines. A high initial antibody response does not mean that antibody levels follow the same course over time across all age groups. The antibody increase after breakthrough infection should likewise be interpreted specifically as an immune response observed after infection.
The available evidence is an abstract reporting an analysis of immune markers in 64 healthy adults. The exact effect sizes and confidence intervals, total follow-up period, and numbers of participants analyzed by breakthrough infection status could not be confirmed. Assessing protection against infection or severe disease, or the optimal booster interval, requires further evidence directly evaluating those outcomes.
The study is described in the Vaccine article abstract.
BACKGROUND: The emergence of highly mutated SARS‑CoV‑2 variants challenges vaccine protection. Evaluating long‑term immune protection from boosters is crucial. The experiment compares neutralizing antibody dynamics and ACE2‑RBD binding inhibition induced by mRNA and inactivated vaccine boosters, and assesses the impact of breakthrough infections and age on immune responses. METHODS: This study is based on a previous randomized, double‑blind, parallel controlled trial. Healthy participants aged ≥18 who had received ≥3 inactivated COVID‑19 vaccine doses. Volunteers (32 aged 18‑59 and 32 ≥ 60) were stratified by age and vaccine type (24 mRNA, 8 inactivated in each age group). Pregnant women, those with severe chronic diseases or a history of allergies are excluded. Neutralizing antibodies were measured via microneutralization assay, and ACE2‑RBD binding inhibition by high‑sensitivity electrochemiluminescence. The study assessed changes in antibody levels and ACE2‑RBD binding inhibition pre‑ and post‑infection across age groups to evaluate vaccine efficacy and durability. (Registed number: ChiCTR2200064575). RESULTS: The neutralizing antibody titers from mRNA vaccine showing stronger and more consistent responses against the original strain and variants like XBB and BA.5. After breakthrough infections, mRNA‑vaccinated individuals show a significant and lasting boost in antibodies, while the increase in inactivated vaccine recipients is modest. By age, mRNA‑vaccinated people over 60 experience a faster antibody decline post‑vaccination, whereas the inactivated vaccine group sees an initial rise at three months before declining. For ACE2‑RBD binding inhibition, mRNA vaccines maintain higher early‑phase rates, while inactivated vaccines show a delayed rise at three months followed by decline. CONCLUSIONS: mRNA vaccines induce stronger neutralizing antibodies and broader immunity than inactivated vaccines. Breakthrough infections boost antibody levels more in mRNA recipient
In subsequent vaccine studies involving adults who have received several doses of an inactivated vaccine, these results may inform assessments of both initial antibody levels and their rate of decline. For example, when designing booster comparison trials that include older adults, researchers could consider the antibody decline observed after CS-2034 when setting follow-up time points and analyze results by breakthrough infection history. This is a conditional example of how the findings could inform research design. The abstract alone cannot determine when antibody testing should be performed in clinical practice or establish vaccination intervals. The study was small and focused on healthy adults, which also limits generalization to people with severe chronic diseases, among others.